Sarepta Therapeutics’ (SRPT) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $202.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also commented on SRPT. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective on the stock. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Scotiabank assumed coverage on shares of Sarepta Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price for the company. Royal Bank of Canada cut their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Finally, Piper Sandler cut their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $167.41.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $73.45 on Tuesday. Sarepta Therapeutics has a 52 week low of $73.06 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm’s 50-day simple moving average is $108.20 and its 200 day simple moving average is $118.54. The firm has a market capitalization of $7.13 billion, a PE ratio of 58.76 and a beta of 0.79.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its position in Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after purchasing an additional 12,000 shares in the last quarter. Geode Capital Management LLC increased its position in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $3,829,000. Summit Partners Public Asset Management LLC increased its position in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.